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ABSTRACT 
In dogs with osteosarcoma (OS), pre-treatment serum bone alkaline phosphatase (BALP) 
activity is recognized as a prognostic factor; however, biologically- linked causation for this 
clinical observation requires further exploration. Recent data demonstrated that BALP correlates 
with OS burden in dogs; yet, every dog with advanced macroscopic disease will not present with 
BALP elevations, indicating additional factors contribute to BALP activities.  Given that BALP 
exists as a glycosylphosphatidylinositol (GPI)-anchored membrane protein and serves as an 
osteoblast differentiation marker, the purpose of this study is to investigate alternative biologic 
mechanisms that could explain an elevation in BALP in dogs with OS. We hypothesize that 1) 
canine osteosarcoma cells will possess the endothelin (ET)-1/endothelin A receptor (ETAR) 
signaling pathway; 2) blockade of endothelin signaling will attenuate pro-tumorigenic activities 
in canine OS cells; 3) blockade of endothelin signaling will attenuate BALP activity; and 4) 
serum BALP activity in naturally-occurring OS-bearing dogs will correlate with tumors that are 
more osteoblastic in nature than osteolytic as measured via DEXA scan. 
The expression of the endothelin axis in canine OS cells was investigated by 
demonstrating protein expression by western blot analysis. The effects of ETAR antagonism 
using ABT-627 on canine OS cells was investigated by characterizing perturbations in 1) cell 
proliferation by colony forming assays; 2) cell survival using changes in phosphorylation of Akt 
pathway and Jun/AP-1 pathway by western blot analysis; 3) cell migration by quantitative 
analysis; 4) BALP activity by cytochemistry; and 5) BALP activity via ELISA and 
corresponding western blot analysis. Naturally-occurring OS-bearing patients were utilized to 
determine if serum BALP activity correlated with osteoblastic tumors as determined via DEXA 
scan. 
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The endothelin axis is expressed in canine OS cells indicating a possible 
autocrine/paracrine signaling pathway. Exposing canine OS cells to ABT-627 results in 
decreased proliferation, survival, and migration of canine OS cells in vitro. Exposure to ABT-
627 also resulted in decreased BALP expression and activity in canine OS cells. Upper and lower 
quartile relative bone mineral densities, when accounted for tumor size, correlate with BALP 
with a propensity for more osteoblastic tumors to have an elevation in BALP. In conclusion, the 
endothelin axis is expressed in canine OS and, upon attenuation of the pathway, tumor-derived 
growth and survival advantages are inhibited and BALP expression and activity is decreased. 
Clinically, patients with more osteoblastic tumors as measured via DEXA scan, have elevated 
serum BALP activity. This study’s findings are the first to provide a link between increased 
BALP activity and a possible underlying biologic mechanism explaining the poor prognosis 
associated with this biomarker.  
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CHAPTER 1 
INTRODUCTION 
 
Elevated serum alkaline phosphatase is a well-documented negative prognostic factor in 
both dogs and humans with appendicular osteosarcoma (OS) resulting in shorter disease-free 
intervals and survival times (1–9). Found on both normal and malignant osteoblasts, bone 
alkaline phosphatase (BALP) has been identified as a necessary factor for the initiation of 
mineralization; however, it is not required for continuation of the process (10–12).  Serum BALP 
activity is an index of osteoblastic bone formation with increased measurements in certain 
human cancers that are characterized by osteoblastic bone metastasis, mainly prostatic cancer 
(13–19).  The precise function of BALP in bone remains to be completely identified as well as 
the exact biologic explanation for its poor prognostic association with OS bearing patients.  
Elucidation of the biologic mechanism for its association with a poor prognosis may help to 
identify novel therapies for the adjuvant treatment of OS in an effort to increase survival and 
quality of life in these patients. 
In humans, and more recently in dogs, a correlation between serum BALP and tumor 
burden has been identified indicating that larger primary tumors or patients with metastatic 
disease dictate serum BALP levels, and thus a shorter metastasis-free survival and overall 
survival (20–24). Clinically, this link between serum BALP and tumor burden is not always 
evident. Some patients with a great degree of tumor burden, through primary tumor size or 
presence of metastases, do not show an elevation in serum BALP indicating that there are likely 
other biologic mechanisms, in addition to tumor size, that contribute to an elevated serum BALP 
in dogs with OS. 
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Endothelin-1 (ET-1) is a potent peptide, originally discovered to be expressed by vascular 
endothelial cells, that has been shown to play a pivotal role in osteoblastic disease processes, 
mainly through mediating cell differentiation and migration of bone cells (25–28).  Endothelin-1 
inhibits osteoclasts from resorbing bone, stimulates osteoblast proliferation, and increases 
expression of osteopontin, osteocalcin, and bone alkaline phosphatase, resulting in promotion of 
bone formation (29–32).  These effects are mediated through endothelin A receptor (ETAR) and 
are attenuated through antagonism of this receptor.  Selective antagonists of ETAR are able to 
block the proliferative and survival effects of ET-1 on osteoblasts and prostate cancer cells (33–
38). 
The purpose of this study was to investigate additional biologic mechanisms, aside from 
tumor size, elucidating the prognostic relevance of serum BALP activities in appendicular OS-
bearing dogs. The objectives of this study were 1) to identify expression of the endothelin axis in 
canine OS cells; 2) to evaluate pro-tumorigenic activities in vivo of canine OS cell lines 
following exposure to various concentrations of exogenous ET-1 and endothelin receptor 
antagonism with ABT-627; 3) to determine the effects of endothelin A receptor antagonism on 
BALP activity in vitro; and 4) to evaluate the relationship between serum BALP activities and 
relative bone mineral density (rBMD) measured via dual energy x-ray absorptiometry (DEXA) 
scan. We hypothesized that 1) canine OS cells will possess the ET-1/ETAR signaling pathway; 2) 
blockade of endothelin signaling will attenuate pro-tumorigenic activities in OS cells including 
survival and migration pathways; 3) blockade of endothelin signaling will attenuate BALP 
activity; and 4) serum BALP activity in naturally-occurring OS-bearing dogs will correlate with 
tumors that are more osteoblastic in nature than osteolytic as measured via DEXA scan. 
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1. Bone alkaline phosphatase 
2.1.1. Origin of alkaline phosphatase 
Alkaline phosphatase (ALP) consists of a group of heterogeneous isoenzymes involved in 
the hydrolysis of monophosphate esters at an alkaline pH (39).  There are three measurable 
isoforms of ALP found in the serum of dogs, including liver, bone (BALP), and corticosteroid 
isoforms, among other immeasurable isoforms due to extremely short half-lives (39–41).  The 
corticosteroid isoform is coded by the intestinal ALP gene and the liver and bone isoforms are 
coded by the same gene, the tissue non-specific ALP gene (42).  Post-translational modifications, 
mainly glycosylation, result in these different isoforms of the tissue non-specific isoenzyme of 
ALP (43). 
 
2.1.2. Function and attachment of BALP via a GPI-anchor 
Bone alkaline phosphatase, the bone-specific isoform of ALP, is localized to the outer 
membrane of normal and malignant osteoblasts via a hydrophobic glycosylphosphatidylinositol 
(GPI) anchor and is necessary for the initiation of mineralization (10–12,44–46). Release of 
BALP into circulation, where it is measurable, involves enzymatic cleavage of this GPI-anchor 
which can be performed by various GPI-specific phospholipases (47–52). Bone alkaline 
phosphatase activity in serum serves as a biomarker of the rate of osteoblastic bone formation in 
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mammals (18,53); however, its precise function in bone biology and pathobiology is still 
undetermined. 
Glycosylphosphatidylinositol-anchors are a class of lipid anchors involved in the covalent 
linkage of proteins, including enzymes, receptors, cell adhesion molecules, and differentiation 
antigens to the outer leaflet of the plasma membrane of eukaryotic cells (45,49,54). These 
anchors were first described in studies investigating membrane-bound proteins including tissue 
non-specific alkaline phosphatase (55), the Thy-1 antigen of rodent thymocytes and neurons, and 
variant source glycoproteins (VSG) of Trypanosoma brucei (45,56). Because of the tremendous 
amount of VSGs/organism, attached to the plasma membrane by a GPI-anchor, the African 
trypanosome was the perfect model for investigation of the structure of the anchor. The core 
structure of GPI-anchors was determined to be composed of a tetrasaccharide which is 
glycosidically linked to the 6-hydroxyl group of phosphatidylinositol (PI) on one end and linked 
via a phosphodiester bond to ethanolamine phosphate. Finally, this ethanolamine phosphate head 
attaches to the carboxyl-terminal residue of the attached extracellular protein (45), (Figure 2.1). 
Synthesis and attachment of the GPI-anchor to proteins occur in the endoplasmic 
reticulum (ER), with subsequent post-translational modifications being processed in the Golgi 
apparatus. First, the protein is attached to the ER membrane and the N-terminal leader peptide is 
split with a peptidase. The carboxyl-terminal of this resulting protein is then bound to the lumen 
side of the ER membrane and translocated to the site of transamidase complex and presence of 
the GPI-precursor via the chaperon protein, binding immunoglobulin protein. Through the 
actions of transamidase complex and processing of the carboxy-termini, the ethanolamine head 
of the GPI precursor is able to attach to the protein rendering a GPI-anchored protein that is 
ready for transfer through the Golgi apparatus (57). In the transport process from the ER to the 
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plasma membrane, GPI-anchored proteins traverse through the trans-Golgi network in 
glycosphingolipid (GSL)-associated forms, or rafts (58–60), (Figure 2.2). 
Revelation of the structure and synthesis of this anchor allowed researchers of multiple 
disciplines to document the presence of over 100 GPI-anchored proteins. These proteins most 
notably include acetylcholinesterase, exofacial ectoenzymes such as 5’-nucleotidase (5’-NTase), 
and tissue non-specific ALP (61). Variations in the structure of GPI-anchors of varying 
membrane-bound proteins were discovered demonstrating species and tissue specificity of these 
proteins (49). These variations in structure were later discovered to induce resistance from 
cleavage by various enzymes involved in release of these GPI-anchored proteins (45,62–64). 
 
2.1.3. Release of GPI-anchored proteins 
Glycosylphosphatidylinositol-anchors are susceptible to cleavage by various 
phospholipases including bacterial phosphatidylinositol-phospholipase C (PI-PLC), GPI-specific 
phospholipase C (GPI-PLC), and GPI-specific phospholipase D (GPI-PLD) (47,50–52,65–69).  
Phospholipases are enzymes that hydrolyze various bonds within phospholipids into fatty acids 
and lipid products (Figure 2.3). Glycosylphosphatidylinositol-specificity indicates that activity is 
directed specifically towards the GPI-anchor with little to no activity towards other 
phospholipids (45). If released by the activity of a phospholipase, an anchorless form of BALP 
would be expected to be found in serum; however, in vitro studies have identified an anchor-
intact, insoluble form that is more commonly released from osteoblasts (70). In vivo, BALP 
circulates in an anchorless form indicating that the released anchor-intact form must be 
converted to the anchorless form that is soluble and found in circulation. Thus, multiple 
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pathways for the release of BALP and subsequent entrance into circulation have been accepted 
including release of an anchorless form into circulation via phospholipases, release of an anchor-
intact form which could be generated by membrane fragmentation or matrix vesicle formation, or 
a combination of the two (71–73).   
 
2.1.3.1.Release of an anchorless form via phospholipases 
Phospholipases are divided into four different classes based on the site of catalytic 
activity with further subdivision into families within each class. Phospholipase A (PLA) is 
divided into two families, phospholipase A1 (PLA1) and phospholipase A2 (PLA2). These 
phospholipases hydrolyze the acyl group attached to different positions of the 
glycerophospholipids liberating free fatty acids and lysophospholipids. Phospholipase B is used 
to describe a phospholipase with both PLA1 and PLA2 activities (Figure 2.4). Neither of these 
phospholipases has been shown to be involved in cleavage of GPI-anchors, likely due to the 
intra-membranous localization of the cleavage site. Phospholipase C (PLC) and phospholipase D 
(PLD) are both considered phosphodiesterases, enzymes with activity towards phosphodiesterase 
bonds such as in the GPI-anchor. Phospholipase C cleaves the polar head phosphate from 
glycerophospholipids resulting in the production of diacylglycerol (DAG) and inositol-1,4,5-
trisphosphate (IP3) which continue signal transduction through the activation of protein kinase C 
(PKC) and intracellular calcium release (74–76), (Figure 2.5). Phospholipase D cleaves the 
terminal phosphodiester bond of the glycerophospholipid near attachment to the cellular 
membrane between the inositol and the phosphate of the structure (45). 
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Initially, it was found that cleavage of GPI-anchors was inducible with bacterial PLC 
(77). An endogenous form of PLC was then discovered in several mammalian cells and tissues 
where GPI-anchored proteins are expressed which was then termed GPI-PLC due to its similarity 
to a membrane-associated GPI-PLC found in the parasite Trypanosoma brucei (78,79). Due to its 
low circulating plasma levels, however, it is suspected that GPI-PLC does not have much activity 
in vivo (80). Another difficulty with this specific phospholipase entails its cellular location.  In 
immunogold labeling studies, it was determined that GPI-PLC is located on the cytoplasmic 
surface of intracellular vesicles. This localization within the cell complicates proposed 
involvement in cleavage of an extracellular target (81). Alternatively, this phospholipase could 
be involved in cleavage of the GPI-anchor following its assembly in the endoplasmic reticulum, 
prior to attachment outside of the cell, leading to formation of the anchorless form of the 
attached protein released in membrane vesicles.   
Instead, GPI-PLD, an enzyme with high specificity for the GPI-anchor and presence in 
plasma, has been proposed to serve as the enzyme with activity towards this substrate (47,51,68). 
Studies utilizing the addition of exogenous GPI-PLD purified from bovine serum to cell cultures 
revealed undetectable changes to alkaline phosphatase levels into the culture medium (66,68). 
Concurrent treatment with detergents demonstrated alleviation of this inhibition and resulted in a 
significant release of the GPI-anchored protein into the medium (66). Thus, GPI-PLD was not 
active against the GPI-anchor of cell surface proteins unless in the presence of a detergent 
indicating that this anchor may be protected by the phospholipid bilayer of the cell membrane. 
Potentially, this could be a protective mechanism against the effects of GPI-PLD in vivo. With 
many cells of the body in circulation containing GPI-anchored proteins, it would be detrimental 
for circulating phospholipase activity to function without some level of regulation. Otherwise, 
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many of these GPI-anchored proteins would be immediately released as they come in contact 
with these circulating phospholipases. As with GPI-PLC, an alternative structure into which 
BALP is released, such as a membrane vesicle or membrane fragmentation, may be able to 
explain how these phospholipases are able to function in vivo. 
 
2.1.3.2.Release of an anchor-intact form of BALP 
An alternative process of BALP release results in an anchor-intact, insoluble form to be 
released (70). As previously mentioned, this insoluble form must then be processed into the 
soluble form, again through loss of the GPI-anchor that is still intact. Thus, this alternative 
process would likely still require some phospholipase activity; however, it is suspected that 
alternative structures in which BALP can be presented to the phospholipases, either through 
matrix vesicles or membrane fragmentation, may be more susceptible to subsequent cleavage 
without the need for a detergent. In vitro studies have shown that the majority of BALP released 
from human osteoblasts is in an insoluble form representing an alternative release mechanism 
aside from GPI-specific phospholipase activity (70,71).   
During the process of apoptosis, membrane fragmentation results in the formation of 
plasma membrane vesicles as part of the regulation of controlled cellular death pathway (82–86), 
(Figure 2.6). Evaluation of osteoblastic cells undergoing apoptosis has revealed that the 
controlled release of membrane vesicles containing alkaline phosphatase is an important aspect 
of calcification (87–91). Consistent with this finding, human OS cells induced to undergo cell 
death were shown to have an elevated release of BALP while apoptosis inhibitors reversed the 
rise in BALP (53). Interestingly, human osteoblast-line cells from normal bone demonstrated the 
same release of BALP under the same conditions. These findings support a hypothesis that 
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elevations in BALP are associated with apoptosis, and thus, are associated with osteoblast 
turnover. 
 
2.2. Canine osteosarcoma  
2.2.1. Overview 
Osteosarcoma (OS) is the most common primary bone tumor of dogs and is analogous to 
human OS. It is an aggressive, highly metastatic tumor originating from malignant osteoblasts 
and accounts for approximately 85% of skeletal malignancies (92,93). An estimated 10,000 dogs 
and 1,000 children per year develop OS in the United States alone (92,94). In dogs, OS occurs 
primarily in middle-aged to older large to giant breeds with a median age of 7 years and a 
bimodal age distribution with a second peak around 18 to 24 months (95). Approximately 75% 
of canine OS lesions occur in the appendicular skeleton at the metaphysis with a 2:1 predilection 
for the forelimbs to the pelvic limbs (96). The most commonly affected anatomical sites are the 
distal radius and proximal humerus followed by the distal femur, proximal tibia, and distal tibia 
(93,97). With a high incidence of approximately 10% of all diagnosed canine tumors and a more 
aggressive disease course as compared to human OS, canine OS serves as a very valuable 
comparative tumor model for evaluation of therapeutic targets to improve outcomes for both 
humans and canines (98,99). 
Primary OS lesions grow in an expansile, destructive manner and are associated with a 
great degree of pain most likely due to microfractures or disruption of the periosteum (92,100). 
Osteolysis, atypical bone production, or both processes concurrently may be seen 
radiographically and histologically. At presentation, clinical signs may range from a chronic 
progressive lameness to acute non-weight bearing lameness, typically associated with pathologic 
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fracture. A hard swelling may be palpable at the site of the lesion; however, this is not always 
evident on physical examination, especially depending on location of the lesion. Eventually, 90% 
of dogs succumb to metastatic disease with the pulmonary parenchyma being the most frequent 
site of metastasis (95). 
Dogs treated with conventional therapy comprised of limb amputation and systemic 
chemotherapy eventually die of metastatic disease with a median survival time of approximately 
10 months. With amputation alone, dogs have a poor prognosis with a median survival of 
approximately 5 months (101,102). “Limb-sparing” surgical techniques and radioablative 
methods were developed and can be used for tumors of the distal radius, ulna, and tibia with 
similar reported survival times (103–105). Palliative radiation therapy with adjuvant 
bisphosphonate therapy can also be used for dogs in which amputation would not be well 
tolerated or is not performed due to owner wishes (106). Treatment with pain medications alone 
inevitably results in poor quality of life from tumor-associated pain or pathologic fracture within 
a few months of diagnosis. 
 
2.2.2. Prognostic Factors 
In dogs and humans with OS, a limited number of poor prognostic indicators have been 
consistently identified and include advanced stage of disease at presentation (3,107), location of 
tumor (108–112), tumor size (20,23,24), histologic grade (109,113,114), response to pre-
operative chemotherapy (7,107,115), and elevations in serum BALP (1,2,6). Due to 
heterogeneity and lack of completeness of studies, meta-analyses of prognostic factors in canine 
and human OS have only identified these limited prognostic factors (4,107,116). Understanding 
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the biologic mechanism of the cause of these prognostic factors may lead to the discovery of 
novel therapies for the treatment of OS. 
Understandably, metastatic disease at the time of presentation is a poor prognostic 
indicator as treatment options become greatly limited with advanced stage of disease and 
metastatic cells have the propensity to be more aggressive in biologic behavior. Dogs with 
proximal humeral lesions tend to have a poor prognosis speculated to be a result of occult disease 
in a well-muscled area leading to a delay in clinical observation (4). Alternatively, there could be 
inherent differences in the proximal humeral location such as differences in the 
microenvironment caused by differences in biomechanics of the area. In humans with OS, the 
distal lower extremity carries the best prognosis with increased survival times which is similar to 
the distal radius in canine OS (109,117,118). Histologic subtype has been correlated with 
prognosis in humans; however, the response to chemotherapy is typically the overriding 
prognostic factor in these studies  (7,113,119). In canine OS, histologic subtype has not been 
consistently identified prognostic factor and response to chemotherapy is rarely reported because 
of the high rate of amputation prior to chemotherapy. For patients that are treated with limb-
salvage surgery, infection has a positive influence on survival suspected to be due to immune 
stimulation (120,121). In a retrospective study on pediatric OS, larger tumor size was a poor 
prognostic indicator that was significantly predictive of overall survival and event-free survival 
(24). Relative rather than absolute tumor volume was predictive of overall survival in another 
study in pediatric OS (122). Another retrospective study looking at human OS established an 
absolute tumor volume cutoff of 150cm3 as measured radiographically and found that patients 
with volumes over this cutoff had a poorer prognosis than those with a smaller volume (23).  
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2.2.2.1 Elevated BALP in humans and canines with OS and metastatic bone disease 
The most consistently identified prognostic factor in both humans and dogs with OS is an 
elevated serum total alkaline phosphatase (SALP). As previously mentioned, there are multiple 
isoforms of alkaline phosphatase including liver, corticosteroid induced, and bone (BALP) 
forms. Serum measurement of total alkaline phosphatase is an easy, cheap diagnostic test 
available in most veterinary clinics. The corticosteroid- induced form may be present in dogs with 
hyperadrenocorticism, a common concurrent disease process of older dogs, and this form is not 
routinely reported concurrently with SALP. Thus, measurement of SALP alone cannot 
distinguish differing isoforms and hence may not provide an accurate assessment of BALP levels 
in patients with OS and very few studies report serum BALP levels specifically. Bone alkaline 
phosphatase activity is a more accurate biomarker than SALP in the evaluation and continued 
monitoring of patients with OS given the restricted osteoblast source of BALP. 
Because of its cellular restriction to the osteoblast, BALP is a marker of bone turnover 
which can be measured in serum and reflects the bone destruction and cell turnover in conditions 
affecting bone metabolism, including OS and metastatic bone diseases (13–18,53,123). Many 
human OS studies have reported elevated serum or plasma BALP at diagnosis as a poor 
prognostic indicator (21,22,124,125). Some of these studies have demonstrated positive 
correlation between serum BALP activity and local disease recurrence or the presence of 
metastatic disease. Patients with metastatic OS had higher serum BALP levels than those that did 
not develop metastatic disease (21,22). In one of these studies, serum BALP in humans was 
associated with the osteoblastic subtype of osteosarcoma and to the presence of metastatic 
disease with elevated levels indicating a poorer prognosis; however, in this study, multivariate 
analysis only found tumor size to be significantly correlated to serum BALP levels (22). In  
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another study, elevated plasma BALP levels in OS bearing patients at diagnosis was higher in 
patients who developed disease recurrence than in those who showed no evidence of recurrence 
(21). Whether in the setting of disease recurrence or the presence of metastatic disease, a poor 
prognosis with increased BALP is understandable as this enzyme serves as a marker of presence 
of disease; however, the underlying mechanism by which elevations in BALP activity at 
diagnosis prior to the development of metastatic disease results in a poorer prognosis is not yet 
understood. 
Multiple canine OS studies have recognized the negative prognostic factor of an 
increased pre-treatment serum BALP. In a meta-analysis of prognostic factors in canine 
appendicular OS, elevations in SALP resulted in a shorter survival time by 156 days as compared 
to dogs with SALP within the reference range. Disease free interval was also affected negatively 
by elevated SALP levels with a median disease free interval difference of 123 days (4). While 
most studies report on SALP, few studies in dogs have reported the same prognostic significance 
of an elevated pre-treatment BALP activity (2,6,20), similar to what has been reported in human 
literature as discussed previously. In the most recent study, BALP was correlated to tumor 
burden as measured via plain radiographs and concluded that tumor burden may be one 
contributing factor in the explanation of differential serum BALP activities noted in dogs with 
OS (20). Plain radiographs have been used to evaluate tumor burden in a few of the human 
studies mentioned above as well; however, 3-dimensional magnetic resonance imaging (MRI) 
provides the most reproducible measurements of tumor volume in human OS patients due to the 
irregularity and heterogeneous composition of plain radiographs (126,127). One human OS study 
categorized tumor appearance on MRI into 2 main patterns, homogenous and heterogeneous 
types, with a 3rd, miscellaneous, category and found a significant correlation between elevated 
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serum SALP and the heterogeneous type (128). No follow up data on overall survival time or 
disease free intervals was available. While MRI may provide a reliable tool for OS measurement, 
it is not the most practical diagnostic test to perform clinically and radiographs are much more 
accessible in most veterinary practices. 
Elevated serum BALP activity is not an exclusive finding in OS and is commonly seen in 
many non-cancerous pathologic bone diseases, such as Paget’s disease (129), osteoporosis (130), 
fracture healing (19,131,132), hyperparathyroidism (133), and thyrotoxicosis (134), and in 
metastatic bone disease in non-OS cancers, such as prostate, breast, and lung cancers 
(14,16,17,123). These observations support a link to a general reparative osteoblast response 
associated with bone destruction and cell turnover rather than an effect of a malignant osteoblast. 
As mentioned previously, many human studies have demonstrated a correlation to the presence 
of metastatic disease with elevated BALP levels in OS and the recent paper in canine OS 
evaluating elevated BALP activity and tumor burden also demonstrated immunohistochemical 
BALP staining in soft tissue and visceral metastasis (20). This observation supports an effect of 
malignant osteoblasts over a general bone reparative response; however, the known contribution, 
if any, to the serum BALP activity from these soft tissue metastatic lesions is not able to be 
determined. Further support in the link to purely osteoblastic activity in a general reparative 
process is demonstrated in studies that show that BALP is not elevated in metastatic bone 
diseases that are osteolytic in nature (19). 
 
2.3. The Endothelin Axis 
2.3.1. Overview 
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Endothelins (ET) are a family of four 21 amino acid peptides involved in key 
physiological processes in normal tissues and include modulation of vasomotor tone, tissue 
differentiation, development, cell proliferation, and hormone production (135–138), (Figure 2.7).  
The four endothelins are ET-1, expressed primarily in endothelial cells, ET-2, ET-3, and ET-4 
(vasoactive intestinal constrictor). Endothelin-2 is found mainly in kidney and intestinal tissue 
while ET-3 is found in the brain (136,139). These peptides exert their effects by binding to 
endothelin receptors, endothelin A receptor (ETAR) and endothelin B receptor (ETBR), which 
belong to the rhodopsin-like G-protein-coupled receptor superfamily. Aside from its involvement 
in normal physiological processes, the endothelin axis has been shown to have a relevant role in 
various disease conditions including cardiovascular disease (136,140–142), pulmonary disease 
(143), renal disease (144–146), and multiple cancers (137,138,147).   
Endothelin-1 is the only family member to be expressed in endothelial cells and is a very 
potent vasoconstrictor with similarities to the venom of snakes of the Atractaspis family 
(135,148). Endothelin-1 has been the most extensively studied peptide of this family and has 
been implicated in the majority of the disease processes in which endothelins are involved. In 
cancer cells specifically, ET-1 leads to autocrine/paracrine loops that activate aberrant 
proliferation, escape from apoptosis, new vessel formation, immune modulation, abnormal 
osteogenesis, alteration of nociceptive stimuli, invasion, and metastatic dissemination 
(137,138,149). Thus, antagonism of these peptides through receptor blockade provides a viable 
target for cancer therapy. 
 
2.3.2. Endothelin-1 synthesis and processing 
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As with the other endothelins, ET-1 is the product of a gene that codes for a large 
precursor-protein mRNA. The promoter region contains typical CAAT and TATA sequences 
that enable the regulation of transcription along with additional cis elements that provide 
regulatory sites for important stimuli (150). Within these regulatory sites are locations for 
GATA-2 protein binding and AP-1 binding, allowing modulation of the transcription of ET-1 
gene by a variety of growth factors (151,152). The half-life of the produced mRNA is 
approximately 15 to 20 minutes (151). Upon translation of the ET-1 gene, a protein of 203 amino 
acids is produced termed preproendothelin-1 (151). This protein is then selectively processed by 
an enzyme converting it into a 39-amino-acid prohormone, big ET-1. Big ET-1 is secreted and 
circulates in plasma; however, this larger peptide has approximately 1/100 the potency of ET-1 
and must undergo further enzymatic activity to the more active ET-1. Conversion into this final 
and active protein, ET-1, is performed by endothelin-converting enzyme (ECE) -1, ECE-2, and 
chymase (153–159), (Figure 2.8). Quickly following entrance into circulation, in about 4-7 
minutes, ET-1 is cleared through pulmonary circulation (160). With such a short half-life and 
lack of storage in secretory granules, transcription of ET-1 genes occurs very quickly.   
Inducing stimuli  of ET-1 gene transcription include shear stress, stretch, exercise, 
hypoxia, and a variety of growth factors and vascular proteins (161–165). A great majority, 
approximately 75%, of ET-1 secretion from cultured endothelial cells is directed towards the 
vascular smooth muscle (abluminal) side of the cells (166). Thus, it is unlikely that the majority 
of the final product contributes to the circulating ET-1 concentration in plasma and suggests 
more of a paracrine role than as an endocrine hormone. However, it is known that circulating 
plasma ET-1 measurements are a useful marker of disease severity and of prognostic value in a 
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variety of diseases as mentioned previously. Prior to its elimination, ET-1 binds to ETAR and 
ETBR enabling activation of the many biologic pathways that it regulates (167), (Figure 2.9) 
 
2.3.3. Endothelin receptors and G-protein coupled signaling 
As previously mentioned, the effects of ET-1, along with all other members of the 
endothelin family, are mediated through binding to two distinct cell surface endothelin receptors, 
ETAR and ETBR. These G-protein-coupled receptors contain seven hydrophobic transmembrane 
domains with an intracytoplasmic C terminus and an extracellular N terminus. The amino acid 
structure of both receptors is approximately 50 percent identical with 85 to 90 percent 
conservation across mammalian species. Endothelin receptor regulation and production is very 
similar to that of the endothelins. Many of the same factors regulating endothelin production 
stimulate the production of endothelin receptors including hypoxia and many growth factors 
(168). Differences in the C terminus of the two receptors allow for networks of divergent 
intracellular pathways to be activated with different effects. In the vasculature, ETAR is found on 
smooth muscle cells and ETBR is found primarily on endothelial cells and is also expressed on 
smooth muscle cells (169). Activation of ETAR and ETBR found on smooth muscle cells in the 
vasculature results in the profound vasoconstrictive effects of ET-1. However, ET-1 binding of 
ETBR found on endothelial cells results in the release of nitric oxide and prostacyclin which 
cause vasodilation (160), prevention of apoptosis (149), and inhibition of ECE-1 expression in 
endothelial cells (170). Thus, ETBR activation of endothelial cells appears to have counter 
regulatory effects to ETAR. 
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Binding of ETAR by ET-1 results in G-protein-coupled receptors to associate with 
intracellular heterotrimeric G proteins, mainly through a pertussin- insensitive Gq subunit 
associated with ETAR. This association results in the activation of multiple signaling pathways, 
concurrently, that are involved in cell survival and proliferation including activation of 
phosphoinositide phospholipase C (PLC), protein tyrosine kinases, the phosphatidylinositol-3-
kinase (PI3K)/Akt pathway, and the RAF/MEK/MAPK pathway (25,138), (Figure 2.10). Cross-
signaling occurs between cell surface receptors following ligand binding of growth factors 
resulting in expansion of the cellular communication network to activate these multiple signaling 
pathways. In OVCA 433 human ovarian cancer cells, transactivation of epidermal growth factor 
receptor (EGFR) through phosphorylation by ET-1 resulted in MAPK activation via an 
intracellular pathway involving ETAR, β-catenin, and c-Src (171). Because of the multiple 
signaling pathways affected by the endothelin axis, a combination of drugs may allow for 
simultaneous inhibition of these pathways. 
 
2.3.4. Involvement in tumorigenesis and targeting for cancer treatment 
Endothelin-1 and ETAR expression have been identified in a multitude of human cancer 
cell lines and tumors including prostate (29,36,172), ovarian (26), lung (173–175), colon 
(176,177), renal (178), cervical (179), chronic lymphocytic leukemia (180), and glioma (181–
184). Interestingly, in human melanoma cancer cell lines, the ETBR receptor is recognized as the 
main receptor in which ET-1 mediates its effects (185–189). Overexpression of this ET-1/ETAR 
axis has consistently been identified as a poor prognostic factor amongst these cancers. In the 
veterinary literature, there are a couple of reports of endothelin expression in canine cancer. One 
study identified overexpression of ET-1 and ETAR in canine ovarian cancer patients by western 
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blotting and immunohistochemistry of samples of their tumors (190). Another study identified 
ET-1 expression, along with other nociceptive ligands, in canine osteosarcoma cells and patient 
samples via western blotting and immunohistochemistry, respectively (191). While the exact role 
of the endothelin axis in cancer is not clearly understood and is likely multifactorial, and 
blockade of the axis has been found to decrease tumor growth indicating an important role in 
certain cancers (176). Through the activation of ETAR and the multiple signaling pathways 
mentioned above, ET-1 is involved in several aspects of cancer growth and progression including 
cell proliferation, inhibition of apoptosis, angiogenesis, invasion and metastasis, and modulation 
of tumor-infiltrating immune cells (137), (Figure 2.11). Specifically in prostate and breast 
cancer, ET-1 results in proliferation of osteoblasts and the down regulation of osteoclast activity 
resulting in osteoblastic lesions associated with osteoblastic bone metastases and the alteration of 
nociceptive stimuli resulting in malignant bone pain (33,38,192), (Figure 2.12). Thus, inhibition 
of the endothelin axis through degradation of ET-1 or blockade of ETAR became a large area of 
interest in cancer patients which led to the development of endothelin receptor antagonists. 
 
2.3.4.1. Endothelin-1 signaling promotes cell proliferation 
Mitogenic factors, such as ET-1, are regulated through the activation of cellular receptors 
and subsequent transmission of a signal through intracellular signaling pathways which effect the 
nucleus of the cell to promote transcription of genes involved in cellular proliferation. Specific to 
cellular proliferation, ET-1 activates PLC which leads to the formation of inositol 1,4,5-
triphosphate (IP3) and diacylglycerol (DAG) (Figure 2.13). Inositol 1,4,5-triphosphate increases 
the intracellular calcium concentration which leads to the vasoconstriction seen with receptor 
binding of ET-1. Diacylglycerol and calcium stimulate protein kinase C, a known mediator of the 
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mitogenic action of ET-1 through direct activation of the MAPK (193). As mentioned above, 
cross-signaling of EGFR by ETAR activation also results in stimulation of the RAF/MEK/MAPK 
pathway and subsequent transcription of genes involved in DNA synthesis and cell proliferation. 
Spontaneous tumor growth has been inhibited in various human tumor cells including prostate, 
colon, cervical, and ovarian carcinomas through blockade of ETAR, but not ETBR (26,176,194–
196). Activation of ETAR has also been shown to induce proliferation in normal endothelial cells 
in an autocrine manner when ET-1 is upregulated via plasmid transfection (197). In vitro work 
with advanced human prostatic cancer cell lines showed that exogenous ET-1 also enhanced 
mitogenic effects of multiple growth factors including insulin- like growth factor I, insulin- like 
growth factor II, platelet-derived growth factor, basic fibroblast growth factor, transforming 
growth factor (TGF), interleukin-6, and epidermal growth factor (29). These observations 
demonstrate an autocrine role of ET-1 in cellular proliferation through ETAR.  
 
2.3.4.2. Endothelin-1 signaling promotes cell survival 
A variety of growth factors, receptors, and intracellular signaling pathways are involved 
in cell proliferation, survival, and the inhibition of apoptosis, a naturally occurring cell death 
process important to tissue homeostasis and development. Apoptosis transpires through a series 
of transcriptionally activated events resulting in a cascade of cysteine proteases, called caspases 
that result in cell fragmentation and subsequent engulfment by phagocytic cells. Dysregulation of 
apoptosis is a well-known occurrence in cancer development and is recognized as a hallmark of 
cancer (198). Investigation of the mechanisms of evasion of apoptosis has led to the discovery of 
a number of disrupted pathways and aberrant expression of growth factors and their receptors in 
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cancer cells including the anti-apoptotic effects of ET-1 through PI3K activation 
(178,180,199,200). 
The PI3K/Akt pathway includes enzymes involved in cell growth, proliferation, survival, 
differentiation, and motility. Phosphatidylinositol-3-kinase phosphorylation leads to activation of 
the serine-threonine kinase, protein kinase B (PKB)/Akt, which affects important mediators of 
the apoptotic pathways (201). Akt kinase phosphorylates Bad, a member of the Bcl-2 family, and 
also inactivates caspase 9, both resulting in suppression of apoptosis via the intrinsic pathway 
(202,203). Akt also blocks the transcription of death-associated genes including Fas ligand 
(FasL) through phosphorylation and inactivation of a transcription factor of the Forkhead family, 
FKHRL1 (204). In ovarian carcinoma cells, exogenous ET-1 blocked paclitaxel- induced 
apoptosis in a concentration-dependent manner and the addition of an ETAR antagonist was able 
to attenuate this effect (205). Moreover, it was noted that ET-1 activated the Akt pathway in 
these cells and the ETAR antagonist was able to block Akt phosphorylation indicating utilization 
of the PI3K/Akt signaling pathway by the endothelin axis (199). In human colon carcinoma cells, 
not only was ET-1 found to inhibit apoptosis mediated by paclitaxel, it also inhibited apoptosis 
mediated by FasL (186,206).  
Endothelin-1 binding to ETAR results in the upregulation of the PI3K/Akt pathway has 
also been demonstrated in human prostatic cancer (200,207). Endothelin-1 expression in both 
malignant and normal prostatic cells was found to be transcriptionally activated by the β-Catenin 
(β-cat)/T cell factor 4 (Tcf-4) family transcription factors and ET-1 stimulated β-cat/Tcf-4 
signaling via the PI3K-dependent pathway. These findings support a positive feedback loop that 
enhances both signaling pathways to promote proliferation and survival of human prostatic 
cancer cells (207). 
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2.3.4.3. Endothelin-1 signaling promotes migration 
Invasion and metastasis of tumor cells requires the ability of tumor-associated proteinases 
that promote the degradation of the surrounding extracellular matrix (ECM) and the basement 
membrane. Both serine and matrix metalloproteinases (MMPs) have been investigated as key 
components of this process. Matrix metalloproteinases are able to degrade all layers of the ECM 
including collagens, fibronectin, laminin, and the basement membrane (208). Urokinase-type 
plasminogen activator (uPA) is a serine protease involved in tumor progression and metastasis 
through activation of the urokinase receptor (uPAR) and subsequent plasminogen activation 
(209–211). In migrating cells, uPAR localizes to the migrating edge of cells in leading 
lamellipodia and promotes degradation of the ECM (212). Multiple human cancers have 
demonstrated upregulated activity of uPAR and MMPs, specifically MMP-2 and -9, in 
association with metastasis and a poorer prognosis (213,214) 
Acting through ETAR, ET-1 is known to mediate tumor invasion through the activity of 
both of these metastasis-related proteinases (215). Initially in human ovarian cancer patients and 
later in other solid tumor types as well, studies demonstrated that patients with metastatic disease 
had higher serum ET-1 levels suggesting that this endothelin axis may be involved in the 
migration and metastasis process (36,215–217). Endothelin-1 was able to enhance secretion and 
activation of MMPs -2, -9, -3, -7, and -13 along with the uPA/uPAR axis with blockade of the 
ETAR receptor resulting in decreased expression of these proteases and decreased migration and 
invasion of human ovarian carcinoma cells (215). In human OS cells, ET-1 was shown to 
increase MMP-2 and -9 synthesis and activity with ETAR antagonism resulting in decreased cell 
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invasion (218). These and other studies support a role of the endothelin axis in the invasion, 
migration, and eventual metastasis of cancer cells.  
 
2.3.5. The endothelin axis is involved in osteoblastic proliferation 
Osteoblastic metastasis occurs in a number of human malignancies, most commonly seen 
in prostatic and breast cancer. To survive in a hostile foreign environment, metastatic cells must 
be able to establish a microenvironment favoring their own growth. Although there are a few 
proposed mechanisms of metastasis pathophysiology, the seed and soil analogy of Paget is a 
commonly accepted method of tumors that metastasize to bone, initially described in studies 
involving breast cancer. Briefly, tumor cells secrete factors that stimulate osteoblast activity and 
the formation of new bone which is then enriched with osteoblast-derived growth factors that 
favor the local growth of tumor cells (219). Many growth factors have been implemented as the 
supporters of osteoproliferative metastasis including TGFβ, insulin- like growth factors-1 and -2, 
prostate-specific antigen (PSA), uPA, fibroblast growth factors-1 and -2, bone morphogenetic 
proteins, platelet-derived growth factors, and ET-1 (33,36,220–229), (Figure 2.14). Aside from 
the proteases PSA and uPA, the majority of factors listed stimulate osteoblast growth and 
survival directly (33,222,227,229). Through mitogenic and pro-survival effects of these growth 
factors, osteoblasts are stimulated by tumor cells to create an osteoblastic phenotype and 
microenvironmental niche permissive for survival. 
There is concrete evidence that ET-1 stimulates bone formation which was originally 
evaluated in human breast and prostate cancer. These tumor types serve as good models as the 
majority of prostatic bone metastatic lesions are osteoblastic while breast cancer tends to cause 
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osteolytic lesions; however, approximately 25% of bone metastases in breast cancer are 
osteoblastic (230–232). The endothelin axis is known to be involved in cellular proliferation and 
survival of cancer cells as previously discussed; however, in the human prostate cancer model, 
there is also a clear link to the promotion of osteoblastic bone disease. Endothelin-1 has been 
consistently identified as a poor prognostic factor as abnormally elevated plasma levels are noted 
in approximately 58% of men with advanced, hormone-refractory prostate cancer (36). When 
comparing bone metastases to metastases confined to organs, there was a significant elevation in 
ET-1 plasma concentration in men with bone metastases. These concentrations did not correlate 
to tumor burden or serum prostate specific antigen concentrations (37). Contributing to the 
elevation in ET-1, key components of the clearance pathway of ET-1, ETBR and neutral 
endopeptidase (NEP), are downregulated in advanced prostate cancer (29). Neutral 
endopeptidase is a degradative enzyme involved in the regulation of ET-1 (233). 
In a murine model using human breast cancer cell lines, tumor-produced ET-1 was shown 
to stimulate new bone formation in vitro and osteoblastic metastases in vivo via ETAR (37). 
Human breast cancer cell lines have been shown to have express the enzyme that converts 
preproendothelin-1 to ET-1, ECE (234,235). Among multiple growth factors investigated, the 
osteoblastic breast cancer cell line, ZR-75-1, only expresses elevated levels of ET-1 over the 
osteolytic cell line, MDA-MB-231. To further explore the role of ET-1 in new bone formation, 
ET-1 stimulated osteoblast proliferation was only blocked by an ETAR antagonist and not a 
selective ETBR antagonist. Thus, an in vivo study utilizing female nude mice and the osteoblast 
ZR-75-1 cell line was performed to induce osteoblastic metastatic bone disease and determine 
the bone biologic effects of the same ETAR antagonist. Endothelin A receptor blockade reduced 
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osteoblastic metastases in these mice while no effect was seen in mice inoculated with the MDA-
MB-231 cell line (38). 
 
2.3.6. Endothelin-1 increases ALP activity 
Endothelin-1 is a potent peptide that has been shown to play a pivotal role in osteoblastic 
disease processes, mainly through mediating cell differentiation and migration of bone cells (25–
28). Endothelin-1 inhibits osteoclasts from resorbing bone, induces osteoblastic bone formation 
and increases expression of osteopontin and osteocalcin, resulting in promotion of bone 
formation (30–33). In a rat osteoblastic OS cell line (ROS17/2.8), ET-1 exposure was found to 
enhance osteopontin and osteocalcin messenger RNA expression by two-fold whereas, ET-3 had 
no effect demonstrating the signaling pathway is specific to ETAR (31). Osteocalcin is a secreted 
protein that is specific to the osteoblast lineage and osteopontin is a secreted, calcium-binding, 
glycoprotein found in bone matrix. The gene encoding osteocalcin was upregulated by exposure 
of fetal rat calvarial cell cultures to ET-1 and this same study also demonstrated an upregulation 
of alkaline phosphatase genes (32). In another in vitro study, incubation of human osteoblastic 
cells with exogenous ET-1 resulted in a dose-dependent increase in alkaline phosphatase (236). 
All of these proteins are markers of osteoblast function demonstrating a crucial role of ET-1 in 
the osteoblast response. Consistent with these genetic markers of increased osteoblast function, 
ET-1 exposure results in mitogenic effects on osteoblasts via its own direct activity through 
ETAR (237,238). 
Previously, mice were not a great model to use in the investigation of osteoblastic bone 
metastases because they rarely developed metastatic bone lesions and these lesions are typically 
osteolytic. A mouse model in which whole tissue homogenates of canine prostate tissue was 
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implanted near calvarium of nude mice demonstrated that the canine prostate tissue enhances 
new woven bone formation (34). Using this model, the same group evaluated the effects of 
normal canine prostatic tissue homogenates on ALP activity and the effects of ET-1 antagonists 
on ALP activity in vitro. Treatment of cultured rat calvaria with normal canine prostatic tissue 
was shown to stimulate ALP activity in a time- and dose- dependent manner which could be 
blocked by ET-1 antagonists. Calvaria treated with homogenates of tissues from other organs did 
not increase ALP activity (35). These studies suggest that new bone formation and associated 
ALP activity can be stimulated by prostate tissue which can be abrogated by ET-1 antagonists; 
thus, providing a link to ET-1 mediated cell-signaling pathways leading to the activation of 
osteoblasts and associated elevations in ALP activity.  
 
2.3.7. Clinical trials utilizing ET-1 specific antagonists 
The effects of ET-1 are mediated through ETAR and are attenuated through antagonism 
of this receptor (33,37,38).  Selective antagonists of the ETAR are able to block the proliferative 
effects of ET-1 on osteoblasts and prostate cancer cells (33). ABT-627, an endothelin antagonist 
with selectivity for ETAR, has been evaluated most extensively in the human prostatic carcinoma 
model. Osteoblastic bone lesions are very common in men with prostatic cancer resulting in 
severe pain making this aggressive disease a good model for use of ABT-627. In vitro studies 
have shown that this antagonist is able to sensitize prostatic cancer cells to taxane chemotherapy 
via downregulation of survival pathways, NF-κB, Bcl-2, and survivin (239). Blockade of these 
pathways sensitizes cells to be more susceptible to apoptosis; thus, combination therapy with 
chemotherapeutics may increase the amount of apoptosis induced over monotherapy.  The 
addition of taxane chemotherapy to ETAR antagonists reveals that this combination of therapies 
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induces increased levels of apoptosis in vitro on human prostatic cancer cells (239,240). When 
used alone, ABT-627 has no statistically significant improvement in time to progression in men 
with both metastatic and non-metastatic, hormone-refractory prostate cancer (241,242). Another 
study in women with relapsed ovarian cancer evaluated the effect of an ETAR antagonist, 
zibotentan, in combination with paclitaxel plus carboplatin. Unfortunately, there was no 
significant improvement in progression free survival compared to women treated with paclitaxel 
and carboplatin alone (243). Developing novel treatment strategies targeting the endothelin axis 
and associated pro-tumorigenic activities led by this axis may help to improve survival times in 
human and veterinary cancer patients. 
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CHAPTER 3 
MATERIALS AND METHODS 
 
3.1. Cell Lines 
Three canine OS cell lines including HMPOS (provided by Dr. James Farese, University 
of Florida), D17 (purchased from American Tissue Culture Collection, Manassas, VA), and 
Abrams (provided by Dr. Douglas Thamm, Colorado State University) were utilized in this 
study. Jurkat (human T lymphocyte cells) and NIH/3T3 were used as positive control cell lines. 
Cells were cultured at 37˚C in Dulbecco's Modified Eagle's Medium (DMEM) supplemented 
with glutamine (2 mmol/L), penicillin (100 IU/ml), streptomycin (100 IU/ml), and 10% fetal 
bovine serum (FBS) in a humidified atmosphere supplemented with 5% CO2. Cell cultures were 
maintained in subconfluent monolayers and passaged two to three times weekly as necessary. 
 
3.2. Reagents and Antibodies 
Human ET-1 (E7764), Anti-ET-1 antibody (mouse monoclonal; E166), and anti-ETAR 
antibody (rabbit polyclonal; E3651) were purchased from Sigma-Aldrich. Atrasentan 
hydrochloride (ABT-627; HY-15403A) was purchased from MedChem Express. 
Phosphatidylinositol-specific phospholipase C was purchased from Life Technologies (P-6466). 
Anti-phosphorylated Akt antibody (rabbit polyclonal, 9271s), anti-Akt antibody (rabbit 
polyclonal, 9272), and anti-c-jun antibody (rabbit monoclonal, 9165s) were purchased from Cell 
Signaling Technology (Beverly, MA). Horseradish peroxidase conjugated anti-mouse and anti-
rabbit secondary antibodies were purchased from GE Healthcare, UK. Anti-β actin antibody 
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(mouse monoclonal; AC-15) and anti-BALP antibody (mouse monoclonal; ab108337) were 
purchased from Abcam Biochemicals. 
 
3.3. Cell Protein Collection 
Cells were grown in culture until 80-100% confluence was attained.  Media was removed 
and cells were washed twice with PBS. Cells were exposed to trypsin for five minutes to detach 
from culture plate, followed by addition of complete media to neutralize the effects of trypsin. 
Collected cells were then centrifuged at 2,000 rpm at 4°C for 5 minutes. Supernatant was 
removed and the cell pellet was homogenized in 1 ml PBS and transferred to a 1.8 ml eppendorf 
tube before centrifuging at 10,000 rpm at for 4°C for 5 minutes. Supernatant was removed and 
discarded. Cell pellets were stored at -80°C until protein collection and quantification. Cell 
pellets were homogenized with 100-150 μl commercially available Mammalian Protein 
Extraction Reagent (M-PER, Pierce, Rockford, IL) and mixed with fresh Pierce protease 
inhibitor cocktail solution (diluted 1:100 for final working solution). Homogenate was placed on 
a shaker at room temperature for 15 minutes and then centrifuged at 10,000 rpm for 15 minutes 
at 4°C. The supernatant was collected and stored at -20°C until quantification. Cellular protein 
concentrations were determined using a standard assay kit (Bicinchoninic Acid Protein Assay 
(BCA), Pierce, Rockford, IL). 
 
3.4. Western Blot Analysis 
3.4.1. Endothelin-1 and ETAR Expression 
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For each protein expression analysis, 50 μg samples were electrophoresed on 12% 
polyacrylamide gel and then electrophoretically transferred to nitrocellulose membrane. The 
membranes were block with TBST with 5% milk for 1 hour at room temperature. Western blot 
analysis was performed using ETAR and ET-1 antibodies at a concentration of 1:1000 in TBST 
with 5% milk. The membrane was then washed 3 times with TBST and probed with the 
secondary antibody diluted 1:5000 in TBST with 5% milk. The ECL blots were developed using 
ChemiDoc XRS+ molecular imager system (Bio-Rad) with Image Lab software. Band volume 
analysis was done using Image J software (NIH) and results of each of the proteins were adjusted 
for β-actin expression levels used as a loading control. Results reported were derived from at 
least 2 independent experiments. 
 
3.4.2. Akt/phospho-Akt and c-jun/phospho-c-jun expression 
The Abrams, D17, and HMPOS cell lines were grown in complete media to 85% 
confluence. Media was removed and the cells were serum starved for 24 hours. Cells were then 
exposed to experimental conditions including: 1) serum starved only or serum starved for 24 
hours and then stimulated for 1 hour with 2) 10% FBS; 3) DMSO; 4) 100 nM ET-1; 5) 40 μM 
ABT-627; or 6) 40 μM ABT-627 followed by 100 nM ET-1 for 1 hour. Media was removed and 
cells were washed with PBS followed by exposure to trypsin for 5 minutes. Upon release of 
adherence, cells were collected in 0% FBS DMEM to avoid changes in phosphorylation of 
survival proteins due to exposure to supplemented growth media. Membranes were incubated 
with either phosphorylated-Akt antibody at 1:500 in TBST with 5% milk, Akt antibody at 1:1000 
in TBST with 5% milk, or c-jun antibody at 1:1000 in TBST with 5% milk. The membrane was 
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then washed 3 times with TBST and probed with the secondary antibody diluted 1:5000 in TBST 
with 5% milk and developed using a standard chemiluminescence detection kit (Amersham). The 
ECL blots were developed using ChemiDoc XRS+ molecular imager system (Bio-Rad) with 
Image Lab software. Band volume analysis was done using Image J software (NIH) and results 
of each of the proteins were adjusted for β-actin expression levels used as a loading control. 
Results reported were derived from at least 2 independent experiments. 
 
3.5. Colony Forming Assay 
The Abrams, D17, and HMPOS cell lines were seeded overnight in 6-well plates at a 
concentration of 200 cells per 3 ml of DMEM with 10% FBS. Upon adherence of individual 
cells, media was discarded and new media containing different experimental conditions were 
added including DMEM 5% FBS only, DMEM 5% FBS with vehicle (DMSO), or a range of 
ABT-627 concentrations (10-40 μM). Cells were allowed to grow undisturbed for 7 (Abrams) or 
10 (HMPOS and D17) days. Subsequently, wells containing colonies were gently rinsed with 
chilled PBS, treated with 3 ml of solution containing 6.0% glutaraldehyde and 0.5% crystal 
violet for 30 minutes, and then rinsed with tap water. Each of the treatment conditions was 
performed in 3 separate experiments. The number of visible colonies per experimental condition 
were quantified 5 times total by 3 different individuals blinded to treatment conditions. 
 
3.6. Migration scratch assay 
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Qualitative analysis of cell migration was done using the “scratch assay” method (244). 
The Abrams, HMPOS, and D17 cell lines were grown to 80% confluence in 6-well plates in 
DMEM supplemented with 10% FBS (complete media). Six experimental conditions for a 
duration of 24 and 48 hours were evaluated including complete media only, complete media with 
vehicle (DMSO or H2O), a range of ET-1 concentrations (100 pM-100 nM), a range of ABT-627 
concentrations (10-40 μM). A standardized acellular gap was created through cell monolayers 
using a 200ul pipette tip in the middle of each well. Images of the acellular gap were captured at 
time 0 (maximal gap) and 24 or 48 hours later for each experimental condition using an inverted 
microscope (Nikon Eclipse TS100) with a mounted digital camera (SPOT Insight QE model 
#4.2, SPOT Imaging Solutions, Michigan, USA). The average width of 5 representative acellular 
gaps per experiment conditions and cell line were used for quantitative comparisons at 24 and 48 
hours and 2 independent experimental conditions were performed. Each of the treatment 
conditions was performed in duplicate and the assay results are representative of two separate 
experiments. Data was analyzed with Image J software (National Institutes of Health, Bethesda, 
MD).   
 
3.7. Cytologic Detection of BALP Activity 
The Abrams, D17, and HMPOS cell lines were all plated into 0.5 ml chamber well slides 
at a concentration of 25,000 cells per well and allowed to adhere overnight in supplemented 
media. The media was then removed and the cells were exposed to serum starved media for 48 
hours with 1) no additive, 2) DMSO, 3) 40 μM ABT-627, and 4) 40 μM ABT-627 for 30 minutes 
followed by 100 nM ET-1 for 48 hours. The media was then removed and chambers were 
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washed with PBS. The slides were allowed to dry and were then stained with nitroblue 
tetrazolium chloride/5-bromo-4-chloro-3- indolyl phosphate toluidine salt (NBT/BCIP), an ALP 
substrate, as previously reported (245). Briefly, slides were incubated for 8-15 minutes at room 
temperature with sufficient amounts of NBT/BCIP to coat the slide. Slides were rinsed with 
water, blotted dry, and examined microscopically. Positive staining was indicated by brown to 
black staining of the cell surface. Three representative images of each chamber containing 
approximately equivalent cell densities were taken and quantitative analysis was performed on 
pixel intensity between treated and untreated conditions. 
 
3.8. In vitro  BALP ELISA 
HMPOS and Abrams cells were plated at a density of 5 x 105 cells/well in 6-well plates 
in 3 mls of 10% FBS DMEM. After allowing cells to adhere overnight, the media was removed, 
the plates were washed gently with PBS, and cells were exposed to serum free media with 
varying conditions for 48 hours including 1) serum starved DMEM only, 2) DMSO, 3) 100 nM 
ET-1, 4) 40 μM ABT-627, and 5) 40 μM ABT-627 for 30 minutes followed by 100 nM ET-1 for 
48 hours. Media was removed, and cells were washed gently with 1 ml PBS, than scraped for 
collection. Supernatant was removed and the cell pellet was resuspended in 0.5 ml PBS with 0.5 
Units phosphatidylinositol-specific phospholipase C (PI-PLC) isolated from Bacillus cereusa 
and incubated for 30 minutes at 37°C. After incubation, cells were pelleted and the supernatant 
was collected for quantitative analysis with a commercial ELISA (MicroVue BAP EIA kit, 
Quidel, San Diego, CA) test kit utilizing a murine monoclonal anti-BALP antibody. 
34 
 
Protein concentrations were determined in aliquots of each of the cell extracts via BCA 
analysis. This cell layer protein was used as an index of cell number which could have varied 
after exposure to the different conditions. BALP activity from the ELISA was corrected for the 
cell protein layer by dividing the calculated Units by the μg of cell protein (U/μg). 
For additional assessment of the amount of membranous cleaved BALP released into cell 
culture media, a 20 μl aliquot of supernatant derived from the varying conditions after PI-PLC 
incubation was used for western blot analysis. A rabbit monoclonal anti-human/mouse BALP 
antibody was utilized at a concentration of 1:1000 incubated overnight at 4°C followed by anti-
rabbit secondary antibody at a concentration of 1:1000 for 1 hour at room temperature.  
 
3.9. Clinical Population 
The study included dogs with OS that were evaluated at the University of Illinois Cancer 
Care Clinic between 2003 and 2012. All dogs had a diagnosis of appendicular OS confirmed by 
either histopathology or cytology with concurrent positive ALP staining (245). All dogs included 
in the study had orthogonal radiographs of the primary tumor, 3-view thoracic radiographs, 
DEXA scan, and urine and serum collected at the time of diagnosis. Study candidates were 
excluded if they received previous treatment including radiation, chemotherapy, or IV 
bisphosphonates and if they had radiographically apparent pulmonary metastases or metastases 
to other distant sites at the time of diagnosis. After their initial visits, all dogs were treated 
palliatively for OS, receiving coarse-fraction radiation treatment with or without an IV 
aminobisphosphonate. Dogs were re-evaluated at 28-day intervals, at which time serum and 
urine were collected. When owner consent was given, necropsy was performed at the time of 
euthanasia. 
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3.10. Serum BALP ELISA 
Serum was collected at the time of initial presentation, and samples were stored at -80°C 
until analysis. Serum BALP was evaluated with a commercial ELISA (MicroVue BAP EIA kit, 
Quidel, San Diego, CA) test kit utilizing a murine monoclonal anti-BALP antibody, previously 
validated for use in dogs. Reference range for dogs ≥2 years of age is 0–14 U/L (reflects mean 
activity ±2 standard deviations) (246). 
 
3.11. Relative Bone Mineral Density of Primary Tumor 
At initial presentation and every subsequent visit, DEXA (QDR-4500W, Hologic, 
Bedford, MA) scans were performed to measure rBMD of the primary tumor and an equivalent 
anatomic area of the unaffected contralateral limb. Dogs were sedated (butorphanol, 
dexmedetomidine, and atropine) and positioned in sternal or lateral recumbency for forelimb or 
hind limb lesions, respectively. Bone mineral density of the primary tumor was divided by BMD 
of the contralateral normal limb to determine rBMD as previously described (106). For purposes 
of this study, a total of 45 dogs were analyzed. The upper and lower rBMD quartiles were 
utilized as arbitrary cutoffs for the generation of osteoblastic and osteolytic categories, 
respectively. To account for tumor size, a ratio of rBMD to the longest tumor measurement as 
defined by response evaluation criteria in solid tumors (RECIST) was formed. 
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3.12. Statistical Analysis  
The distribution of the continuous variable data was evaluated using the Shapiro–Wilk 
test, skewness, kurtosis, and q–q plots. Data that were not normally distributed were log 
transformed to meet the assumption of normality. One-way ANOVA was used to evaluate for 
differences between groups, with Dunnet’s comparison test to detect a difference between 
control and experimental conditions. A Pearson product-moment correlation coefficient was used 
to assess the relationship between pretreatment serum BALP and rBMD. Statistical calculations 
were performed using commercial software programs. P < 0.05 was considered statistically 
significant for all analyses. Statistical analysis was carried out using a commercially available 
software program (GraphPad InStat, Version 3.10).  
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CHAPTER 4 
RESULTS 
4.1 Endothelin-1 and ETAR are expressed in osteosarcoma cell lines 
Immunoblotting analysis demonstrated translation of ETAR and ET-1 messenger 
ribonucleic acid (mRNA) into protein in all cell lines (Figure 4.1). Expression of the 23 kDa 
protein was detected in all experimental cell lines demonstrating ET-1 protein expression. 
Expression of the 29 kDa protein was detected in all cell lines including the positive control cell 
line, Jurkat, demonstrating ETAR protein expression. 
 
4.2. Endothelin A Receptor inhibition affects cell survival signaling 
4.2.1. ABT-627 variably attenuates ET-1 induced Akt phosphorylation 
Akt is known to protect cells from apoptosis and phosphorylation of this protein must 
occur for the signaling pathway to be activated. Thus, phosphorylation of Akt would be expected 
to occur in conditions in which cell survival is stimulated while phosphorylation would not be 
expected in cell conditions exposed to an inhibitor of cell survival. Immunoblotting analysis 
identified bands at the expected weights of 57 kDa indicating expression of both Akt and 
phospho-Akt  in the canine OS cell lines Abrams and HMPOS. In both cell lines, increased 
phosphorylation of Akt was detected after ET-1 exposure to serum-deprived cells and this was 
equipotent with FBS stimulation (Figure 4.2a,b). ABT-627 treatment alone appeared to have an 
effect in attenuating phosphorylation of Akt when compared to the control and vehicle conditions 
while pre-treatment with ABT-627 for 30 minutes prior to ET-1 stimulation resulted in a further 
decrease in Akt phosphorylation.  
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4.2.2. ABT-627 attenuates ET-1 induced c-jun phosphorylation 
In both the positive control cell line, NIH/3T3, and in Abrams and HMPOS cell lines, 
immunoblotting analysis identified bands at the expected weight of 43 kDa, as well as, a band at 
a higher weight, about 55 kDa consistent with the phosphorylated form of c-jun (phospho-c-jun) 
as this antibody recognizes both the phosphorylated and unphosphorylated forms (according to 
antibody manufacturer). Incubation of cells with ET-1 resulted in increased phospho-c-jun to c-
jun when compared to control conditions. Incubation of cells with ABT-627 alone and ABT-627 
followed by ET-1 stimulation resulted in a decreased ratio of phospho-c-jun to c-jun when 
compared to control and vehicle conditions (Figure 4.3).  
 
4.3. Endothelin A receptor antagonism decreases colony forming ability of canine OS 
To determine if antagonism of ETAR affects cell proliferation and survival, colony 
forming assays were performed with varying concentrations of ABT-627. After appropriate 
incubation periods of 7 days (Abrams) and 10 days (HMPOS and D17), there was a consistently 
identified statistically significant difference in the ability of all OS cell lines to form colonies 
when exposed to 40 µM ABT-627 compared to both control and vehicle conditions (p < 0.01), 
(Figure 4.4a-c). The effects of ABT-627 were also statistically significant in the Abrams and 
D17 cell lines at 30 μM ABT-627 (p < 0.01), (Figure 4.4a,b). 
 
4.4. The endothelin axis affects cell migration of canine OS in vitro 
Cancer cells must be able to migrate within the microenvironment to vasculature to be 
able to metastasize to other areas of the body. Thus, we evaluated the effects of ET-1 and ABT-
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627 on cell mobility of all three OS cell lines. An acellular gap was created in confluent cultures 
and the gap was measured at 24 and 48 hours after treatment. Data is represented as a percentage 
of the original gap (time 0), with 0% being a completely closed gap. In the Abrams cell line, 
there was a significant difference in gap closure in all ABT-627 concentrations at the 24 hour 
time point and in both the 30 μM and 40 μM ABT-627 wells (p < 0.01), (Figure 4.5a). In the 
D17 cell line, there was a significant difference seen in the 20-40 μM ABT-627 wells at both 24 
and 48 hours (p <0.01), (Figure 4.5b). For HMPOS, the only significant difference was noted at 
the 40 μM ABT-627 concentration at both the 24 and 48 hour time points (p < 0.01), (Figure 
4.5c). In all OS cell lines that were treated with 100 nM ET-1, the gap was more noticeably 
closed as compared to untreated control and vehicle wells after 24 hours of exposure (p < 0.05), 
(Figure 4.5d-f). There was no significant difference noted in cells treated with ET-1 at any 
concentration at the 48 hour time point since the gaps were closed completely in all conditions 
(data not shown). 
 
4.5. Endothelin A receptor antagonism decreases BALP expression and activity 
4.5.1. Bone alkaline phosphatase activity is decreased following ETAR antagonism as measured 
via cytochemistry 
Exposure of the HMPOS and Abrams cell lines to ABT-627 alone and ABT-627 
followed with ET-1 stimulation resulted in a subjective visual decrease in BALP activity 
compared to the control and vehicle conditions. When quantitative analysis was performed with 
pixel intensity of images taken of the different conditions, there was a statistically significant 
difference in the HMPOS cell line in chambers treated with ABT-627 alone or ABT-627 
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followed by ET-1 compared to control and vehicle conditions (p < 0.001), (Figure 4.6). There 
was no significant difference between any of the conditions in the Abrams cell line.  
 
4.5.2. Bone alkaline phosphatase activity is decreased following ETAR antagonism as measured 
via ELISA 
In an additional method to measure BALP activity following exposure to ETAR 
antagonism, an ELISA was performed on both the Abrams and HMPOS cell lines. Following 24 
hours of treatment with ABT-627 and the combination of ABT-627 followed by ET-1, cells from 
the HMPOS cell line demonstrated decreased BALP activity that was statistically significant 
when compared to control and vehicle treated cells (p < 0.01) (Figure 4.7a). While both of these 
treatments decreased the cell protein layer, there was still a statistically significant difference in 
BALP activity after normalization of the BALP activity to the amount cell protein layer (p < 
0.01), (Figure 4.7b). Treatment of cell lines with ET-1 did not cause significant changes in 
BALP activity. 
Western blot analysis of protein expression of BALP correlated with ELISA findings 
with a decrease in band expression at the expected weight of 75 kDa in the ABT-627 and ABT-
627/ET-1 combination treated cells (Figure 4.7c). 
 
4.6. Serum BALP activity in appendicular OS bearing dogs correlates with bone mineral 
density when accounting for tumor size 
Clinical patients with appendicular OS had DEXA scans of the affected and contralateral 
limbs measured at diagnosis along with serum BALP activity. The upper and lower quartiles of 
dogs with DEXA scans were separated out into osteoblastic (rBMD greater than 1.3) and 
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osteolytic (rBMD less than 0.7) groups (Figure 4.8). When BALP activity was log transformed 
to normalize data, the osteoblastic group demonstrated elevated serum BALP activity when 
compared to the osteolytic group (p < 0.01), (Figure 4.9). To account for tumor size, a ratio of 
rBMD to RECIST was formed and this ratio was correlated with the log BALP activity. A 
statistically significant difference was still appreciated between groups with the osteoblastic 
group having elevated BALP activity compared to the osteolytic group (p < 0.01), (Figure 4.10). 
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CHAPTER 5 
DISCUSSION AND CONCLUSIONS 
In normal physiologic processes, the endothelin axis actively participates in key cellular 
pathways including cell proliferation, apoptosis, angiogenesis, vasomotor tone, and hormone 
production (136). Endothelin-1 signaling through ETAR coordinates various tumorigenic 
properties including cell proliferation, survival, migration, invasion and metastases, and 
angiogenesis (137,138). In regard to malignant bone pathology, ET-1 has been identified as a 
key driver in perpetuating the successful development and progression of skeletal metastases 
particularly for prostatic and breast cancer in humans (37,38,192,230–232). Endothelin-1 
released by malignant cells that have reached a bone microenvironment results in proliferation of 
osteoblasts and the down regulation of osteoclast activity resulting in osteoblastic bone 
metastases (33,37,38,137). Inhibition of ETAR has been shown to decrease the ability of 
metastatic bone lesions to form and has resulted in dampening the effect of ET-1 induced pro-
tumorigenic properties (33,35,176,199,240). 
Accompanying the results derived from studies of human OS cells, the findings of the 
current investigation demonstrate that canine malignant osteoblasts similarly possess ET-1/ETAR 
signaling machinery (174,218). Based upon the co-expression of both receptor and cognate 
ligand, it is plausible that canine OS cells have the potential to exploit autocrine and paracrine 
ET-1 signaling as a mechanism favoring pro-tumorigenesis. Differences in expression were 
minimal between cell lines and HMPOS appeared to have lower ET-1 expression than Abrams 
and D17. 
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It has been well documented in other studies that ET-1 utilizes the PI3K/Akt survival 
pathway as well as the mitogen-activated protein (MAP) kinase pathway and induces expression 
of expression of immediate early response genes (149,199,200,247–249). Activation of PI3K 
through multiple signaling cascades leads to the phosphorylation of Akt. Phosphorylated Akt can 
regulate cell growth and survival through negative regulation of cell cycle inhibitors and effects 
on p53 (250–252). In human prostatic carcinoma cells, it was demonstrated that ET-1 exposure 
resulted in increased expression of pAkt in a time- and dose-dependent manner suggesting 
survival signaling occurs through a PI3K pathway (200). Inhibitors of other survival pathways, 
in that study, were not successful in blocking the effects of ET-1. In another study investigating 
human ovarian carcinoma cells, ET-1 was once again shown to cause phosphorylation of Akt 
which could be attenuated by pre-treatment with an antagonist of ETAR (199). Endothelin-1 
induced phosphorylation of Akt was prevented by treatment with wortmannin, a PI3K inhibitor 
in that study. The results from these studies provide strong evidence that ET-1 signaling through 
ETAR results in a pro-survival effect utilizing the PI3K/Akt survival pathway. 
In an attempt to connect our findings of the pro-tumorigenic properties of ET-1 to 
signaling pathways, we investigated both the PI3K/Akt and JNK survival pathways following 
exposure to ET-1 and ETAR antagonism through immunoblotting analysis of pAkt/Akt and 
phospho-c-jun/c-jun, respectively. Our findings demonstrate activation of Akt by ET-1 which 
could be blocked by treatment with ABT-627 suggesting that ET-1 signals through ETAR to 
induce phosphorylation of Akt. We showed similar findings in Abrams and HMPOS cells when 
evaluating the expression of phospho-c-jun and c-jun, a key transcription factor involved in the 
formation of AP-1 and consequent cell proliferation. Endothelin-1 induced increased expression 
of phospho-c-jun to c-jun while ABT-627 was able to block the phosphorylation of c-jun. These 
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findings suggest that blockade of ET-1 signaling might reduce cell proliferation signals. Induced 
phosphorylation of Akt and c-jun by ET-1 which can be attenuated with ETAR antagonism 
suggests that, similar to human prostatic and ovarian carcinoma, canine OS cells utilize the 
endothelin axis as both pro-survival and mitogenic signaling pathways. 
Given the potential for the existence of an autocrine/paracrine signaling loop in canine 
OS as well as the known role of the endothelin axis in osteoblast proliferation and survival in 
skeletal metastases, the current study explored the effects on canine OS cell migration, 
proliferation, and survival following exposure to ABT-627, a selective antagonist of ETAR. With 
regard to OS cell proliferation and survival, a dose-dependent anti-mitogenic effect of ABT-627 
was demonstrated in the Abrams, D17, and HMPOS cell lines through the use of colony forming 
assays. Maximal reduction of colony formation was noted at the highest concentration of ABT-
627 (40 μM) and correlated well with attenuation of Akt and c-jun phosphorylation. The activity 
of ABT-627 was also effective at the lower concentration of 30 μM. Along with inhibition of cell 
proliferation, we evaluated the effects of the endothelin axis on migration as multiple other 
studies have demonstrated pro-migratory effects of ET-1 (30,208,215,218,253). ET-1 signaling 
blockade with ABT-627 reduced canine OS cell migration in a dose-dependent manner with the 
most profound effect noted at the highest concentration used (40 μM). A dose-dependent pro-
migratory effect of ET-1 was also demonstrated in all three cell lines. Thus, our results show that 
the endothelin axis is involved in multiple pro-tumorigenic processes in canine OS cells. 
Aside from its involvement in pro-tumorigenic processes, the endothelin axis has been 
shown to be an important player in the production of metastatic osteoblastic bone lesions in 
humans (37,192,230–232,254). Upregulation of genes including osteopontin, osteocalcin, and 
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BALP, has been identified following stimulation with ET-1 supporting the peptide’s involvement 
in osteoblastic proliferation and differentiation (31,32). Taking these findings one step farther, 
one group demonstrated that canine prostatic tissue increased ALP activity in cultured rat 
calvaria which could be attenuated by ETAR blockade. With these findings in mind, we 
evaluated the effects of ETAR blockade on BALP activity of canine OS cell lines as measured 
via cytochemistry and ELISA. Corroborating the previous data, in canine OS cell lines, there was 
a strong, negative correlation between cellular BALP activities following exposure to ETAR 
antagonism supporting the hypothesis that ET-1 signaling is linked directly to BALP activity. 
Subjectively, cytochemistry of BALP activity showed a strong difference in staining intensity 
between treated and untreated cells. To account for possible differences in cell survival between 
chambers, and thus the strictly subjective visual appearance of a difference in staining intensity, 
we performed pixel quantification of inverse images of representative areas of each chamber. 
This more quantitative analysis still supported a significant difference between treated and 
untreated chambers in the HMPOS cell line. There was no statistically significant difference in 
the Abrams cell line and this could be due to the decreased basal BALP activity noted in this cell 
line resulting in difficulties to detect changes in intensity of BALP activity. To further 
substantiate the link between BALP activity and the endothelin axis, we performed an ELISA 
measuring BALP activity on the Abrams and HMPOS cell lines. HMPOS cells that were treated 
with ABT-627 alone or ABT-627 followed by ET-1 stimulation demonstrated a marked decrease 
in BALP activity compared to control and vehicle wells. Media from these conditions were 
analyzed for BALP expression via immunoblotting analysis and the results mirrored the results 
of the ELISA analysis. These consistently identified decrease in BALP activity and expression in 
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cells treated with an antagonist of ETAR lends additional credence to the hypothesis that ET-
1/ETAR signaling has the capacity to directly contribute to BALP activity in canine OS cells. 
Multiple studies have identified various prognostic indicators in both dogs and humans 
with OS (1–3,6–9,23,107,109,114–117,119,255). In humans, and more recently in dogs, a 
positive correlation between tumor size and serum BALP activity has been identified with 
elevated tumor size being a poor prognostic predictor of metastasis- free survival and overall 
survival (20,23,24). In our study, we separated dogs with naturally-occurring appendicular OS 
into two groups based upon DEXA imaging. Using the upper and lower quartiles of all dogs 
scanned, thus, dogs with more osteoblastic and osteolytic tumors, respectively, we selected for 
patients with a difference in bone microenvironment. Our hypothesis was that dogs with more 
osteoblastic tumors have an increased number of osteoblasts, a known contributor to BALP 
expression, would have higher levels of serum BALP. Furthermore, we propose that, with our 
evidence that ET-1 is positively correlated to both BALP activity and osteoblast differentiation 
and survival, the elevation seen in serum BALP seen in patients with OS could be an 
epiphenomenon caused by elevated levels of tumor-associated ET-1. We identified that dogs 
with more osteoblastic tumors had significantly higher levels of log serum BALP. To account for 
the previously identified relation to absolute tumor burden, and thus tumor size, we created a 
ratio of rBMD to RECIST and compared this ratio to log serum BALP levels in these patients. 
Once again, there was a statistically significant difference in dogs with more osteoblastic tumors 
when accounting for tumor size to log serum BALP. Thus, differences in bone 
microenvironment, specifically more osteoblastic OS tumors, contribute to the observed 
differential serum BALP activities in dogs with OS. 
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Our study has several limitation to address including the use of a few OS cell lines to 
represent the heterogeneous disease of canine OS. Many of the experiments were in vitro in 
nature which limits the immediate translational significance. While biologically achievable 
human levels were utilized for this study, a pharmacologic study is necessary to determine if the 
same dose if achievable in dogs. Only one ETAR was selected for use in this study; however, 
there are many other compounds target this specific receptor or both endothelin receptors. Thus, 
ABT-627 may not be the most effective compound to have evaluated. We evaluated a couple of 
survival pathways that are well-documented to be affected by ETAR antagonism and it is 
important to recognize that there are still other survival pathways that could be involved in 
endothelin signaling that were not evaluated (199,247–249). While we provide evidence that the 
endothelin axis plays a role in osteoblast survival and BALP activity, and that serum BALP in 
clinical patients is linked to osteoblastic tumors, we have not specifically evaluated the effect 
that ETAR blockade could have serum BALP in vivo in naturally-occurring OS-bearing dogs. 
Further investigation of the effect that ETAR blockade has on serum BALP activity and 
prognosis is necessary to obtain a better understanding of our findings. 
In conclusion, our results showed that canine OS cells express both ET-1 and ETAR 
which are involved in pro-tumorigenic processes including cell migration and survival. To 
explain the relation to underlying signaling pathways of these processes, we evaluated and found 
changes in phosphorylation of survival pathways, PI3K/Akt and JNK, when exposed to ABT-
627. Endothelin A receptor antagonism also demonstrated a negative effect on BALP activity in 
canine OS cells. Utilizing naturally-occurring appendicular OS-bearing dogs, this study provides 
new information in the biologic explanation of elevations in serum BALP and the identified poor 
prognosis, specifically the relation between rBMD and serum BALP when accounting for tumor 
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size, another recognized contributing factor to serum BALP. Additionally, we have provided a 
plausible link between the endothelin axis, a known osteoblast survival signaling pathway, to the 
production of BALP activity. These findings could help elucidate, as part of a multifactorial 
explanation, the biologic mechanism to explain the poor prognostic significance of elevated 
BALP levels in patients with OS.  
49 
 
CHAPTER 6 
LIST OF FIGURES 
Figure 2.1 Structure of GPI-anchored proteins. (From 
http://cms.unige.ch/sciences/biochimie/Reika-Watanabe,124.html) 
 
 
 
Figure 2.2 Process of GPI-anchor protein formation and trafficking to the plasma membrane. 
(From http://www.fbs.osaka-u.ac.jp/organelle-network/eng/research/22/) 
 
 
50 
 
Figure 2.3 Sites of cleavage by PI-PLD and PI-PLC. 
(http://www.cureffi.org/2013/06/29/proteolytic-shedding-of-prion-protein/) 
 
 
 
Figure 2.4 Sites of cleavage of phospholipases. PLB is characterized as an enzyme with 
activity on both PLA1 and PLA2. (Molecular Cell Biology, Sixth Edition. 2008. W. H. Freeman 
and Company. Figure 10-14.) 
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Figure 2.5 Phospholipase C activation results in conversion of PIP2 to DAG and IP3. (From 
http://www.endocrinesurgeon.co.uk/index.php/what-are-cell-surface-receptors-and-second-
messenger-systems) 
 
 
 
Figure 2.6 Formation of extracellular vesicles including exosomes created by resting or 
activated cells, microvesicles created from tumor cells, and apoptotic bodies from apoptotic 
cells. (http://www.extracellularvesicles.org/). 
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Figure 2.7 Amino-acid structure of ET-1. (http://www.europeanurology.com/article/S1569-
9056(08)00169-3/fulltext/endothelin-receptors-as-therapeutic-targets- in-castration-resistant-
prostate-cancer). 
 
Figure 2.8 Regulation and processing of ET-1 from the ET-1 gene in endothelial cells. 
(http://www.endothelins.com/Endothelin%20Biology/) 
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Figure 2.9 Downstream functions of endothelin receptors. Parentheses indicate functions 
infrequently mediated by corresponding receptor. 
(http://www.nature.com/nrc/journal/v3/n2/fig_tab/nrc990_F2.html) 
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Figure 2.10 Endothelin A receptor binding by ET-1 triggers activation of multiple signal 
transduction pathways in cancer cells. Activation of PLC results in mobilization of calcium 
through IP3 and PKC activation through DAG. Along with PTKs, FAK and paxillin, PLC 
activation ultimately results in activation of the RAF/MEK/MAPK pathway. Signaling through 
ETAR also activates PI3K, which results in Akt survival pathway stimulation and increased 
protein translation by the mTOR signaling pathway. PI3K also initiates ILK-dependent GSK-3β 
phosphorylation which results in stabilization of SNAIL and β-catenin ultimately resulting in 
transcription of genes involved in EMT. Cross-signaling through activation of c-Src and 
subsequent transactivation of EGFR is partly responsible for MAPK activation. Finally, ET-1 
promotes COX-1 and -2 expression, PGE2, and VEGF production. 
(http://www.nature.com/nrc/journal/v13/n9/full/nrc3546.html) 
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Figure 2.11 Endothelin-1/ETAR signaling in tumor cells enables several aspects of cancer 
growth and progression. In many cancers, ET-1 results in cell proliferation, cell survival through 
inhibition of apoptosis, angiogenesis, invasion and metastatic spread, and modulation of tumor-
infiltrating immune cells. In prostate and breast cancer, ET-1 induces osteoblast proliferation and 
decreases osteoclastic bone resorption resulting in osteoblastic bone metastases. (Bagnato and 
Rosanò, Internation Journal of Biochemistry & Cell Biology, 40(8), 1443-1451, 2008). 
 
 
56 
 
Figure 2.12 Endothelin-1 stimulates osteoblast proliferation and new bone formation while 
decreasing osteoclast functions. Multiple growth factors are affected and effect ET-1 signaling. 
(http://www.nature.com/nrc/journal/v3/n2/fig_tab/nrc990_F4.html) 
 
 
 
Figure 2.13 Endothelin-1 binding to ETAR results in activation of intracellular PLC and 
subsequent activation DAG and IP3. 
(http://www.nature.com/nrc/journal/v3/n2/fig_tab/nrc990_F3.html) 
 
 
57 
 
 
Figure 2.14 Tumor cells produce multiple growth factors that support the development of 
osteoblastic metastases. 
(http://img.medscape.com/fullsize/migrated/editorial/cmecircle/2005/4898/images/489803.gif) 
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Figure 4.1 Endothelin-1 and ETAR are expressed by canine OS cell lines. Jurkat is a positive 
control for ETAR.  
 
 
Figure 4.2 Effects of ET-1 and ABT-627 on the expression levels of pAkt and Akt in serum 
starved Abrams and HMPOS cells. (a) Increased phosphorylation of Akt in HMPOS cells treated 
with ET-1 and 10% FBS can be seen visually with darkening of the bands. Cells treated with 
ABT-627 and the combination of ABT-627 and ET-1 show decreased band weight. (b) 
Treatment with ABT-627 alone resulted in mild reduction in the ratio of pAkt/Akt while 
incubation with ABT-627 followed by ET-1 stimulation resulted in more marked reductions in 
the Abrams cell line. Mild increases in pAkt/Akt ratio are noted with ET-1 and FBS treated cells. 
 
 
a 
b 
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Figure 4.3 Effects of ET-1 and ABT-627 on the expression levels of phospho-c-jun and c-jun 
in (a) Abrams and (b) HMPOS cells. Treatment with ET-1 resulted in production in the 
expression of phospho-c-jun compared to expression levels of c-jun. Treatment with ABT-627 
alone or followed by ET-1 stimulation resulted in reduction in the ratio of phospho-c-jun/c-jun. 
 
 
 
 
a 
b 
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a 
b 
Figure 4.4 Effects of ABT-627 and ET-1 treatment on colony forming ability of canine OS 
cells. (a-b) In the Abrams and D17 cell lines, there was a statistically significant difference in 
number of colonies formed at 30 μM and 40 μM ABT-627 compared to control and vehicle wells 
(*p < 0.01). (c) In the HMPOS cell line, there was a statistically significant difference in number 
of colonies formed at 40μM ABT-627 (*p < 0.01). 
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c 
Figure 4.4 (cont.) 
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a 
Figure 4.5 Treatment with ABT-627 inhibits while ET-1 promotes cell migration in a scratch 
assay. A monolayer of cells was scratched and cells were then treated with ET-1 or ABT-627 at 
indicated concentrations. Coverage of defect cells was documented by photomicrographs after a 
24hr period incubation. (a) Treatment with ABT-627 inhibited scratch closure in the Abrams cell 
line at all concentrations after 24 hours exposure and at 30 μM and 40 μM ABT-627 when 
incubated for 48 hours (*p < 0.01). (b) Treatment with ABT-627 significantly inhibited the D17 
cell line at 20-40 μM ABT-627 at 24 hours and at 30 μM and 40 μM ABT-627 when incubated 
for 48 hours (*p < 0.01). (c) In the HMPOS cell line, inhibition of scratch closure was seen at 40 
μM ABT-627 at both the 24 and 48 hour exposures (*p < 0.01). (d) Treatment with ET-1 
promoted scratch closure at higher concentrations of 10 nM and 100 nM in the Abrams cell line, 
(e) at concentrations of 1 nM-100 nM in the D17 cell line, (f) and at 100 nM in HMPOS cell line 
(*p < 0.05). Images are representative of 2 separate experiments. 
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b 
c 
Figure 4.5 (cont.) 
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d 
e 
f 
Figure 4.5 (cont.) 
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a 
Figure 4.6 Cytochemistry of OS cell lines following exposure to ABT-627 and combination 
therapy of ABT-627 followed by ET-1. Chamber slides were exposed to varying conditions in 
serum free medium for 48 hours prior to 8 and 15 minute NBT/BCIP incubation times for the 
HMPOS and Abrams cell lines, respectively. Pixel quantification of BALP staining of 
representative areas of each chamber. (a & c) Pictures of BALP ICC slides and corresponding 
inverse images utilized for pixel quantification. (b) The HMPOS cell line demonstrated 
significant decreases in BALP staining after treatment with ABT-627 and combination treatment 
of ABT-627 followed by ET-1 (*p < 0.001). (d) There was no significant difference between 
treated and untreated conditions in the Abrams cell line. 
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b 
c 
Figure 4.6 (cont.) 
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d 
Figure 4.6 (cont.) 
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a 
b 
c 
Figure 4.7 Effects of ABT-627 and combination therapy of ABT-627 followed by ET-1 
stimulation on net release of BALP activity from HMPOS cells as measured via ELISA. 
Replicate cultures (n=2) of HMPOS cells were exposed to varying conditions in serum free 
medium for 24 hours. Bone alkaline phosphatase activity (U/L) was measured in duplicate 
aliquots of the (a) cell-conditioned medium and (b) normalized to cell layer protein. (c) 
Immunoblotting analysis of cell-conditioned medium correlating with BALP activity from 
ELISA. Data shown as group mean values ±SEM. Significant difference compared to control 
and vehicle (*p < 0.01). 
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Figure 4.8 Separation of clinical canine OS patients into upper 25% quartile (osteoblastic) 
and lower 25% quartile (osteolytic) categories as measured by rBMD via DEXA scan. 
 
Figure 4.9 Osteoblastic tumors have significant increases in serum BALP activity when 
compared to osteolytic tumors. (*p < 0.01) 
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Figure 4.10 To account for tumor size as a cause of elevated BALP activity, a ratio of rBMD 
to RECIST was performed and compared to log transformation of serum BALP activity. There 
was a significant correlation between this ratio and serum BALP activity with an increased ratio 
(more osteoblastic tumors) having elevated BALP activity. (*p < 0.01) 
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